Expression of autophagy-related proteins Beclin-1 and LC3A and proliferation marker Ki-67 in calculous and acalculous human gallbladder epithelium.
Autophagy
Beclin-1
Ki-67
LC3A
cholecystitis
gallbladder epithelium
lithogenesis
Journal
Hippokratia
ISSN: 1108-4189
Titre abrégé: Hippokratia
Pays: Greece
ID NLM: 101296613
Informations de publication
Date de publication:
Historique:
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
ppublish
Résumé
Autophagy is an inducible intracellular process that has been studied mostly in cancer and less in inflammatory diseases. To establish the relation between cholecystitis (calculous and acalculous) and autophagy, we studied the expressions of immunohistochemical markers Beclin-1, LC3A, and Ki-67 in gallbladder epithelium and their significance in the induction of autophagy. Adult human gallbladder tissues were obtained from 100 patients (45 male, 55 female) who underwent cholecystectomy. According to the findings, the patients were divided into two groups: group A (calculous gallbladder: 24 male, 46 female; mean age 52.6 ± 16.0 years) and group B (acalculous gallbladder: 21 male, nine female; mean age 65.3 ± 12.4 years). The expressions of immunohistochemical markers Beclin-1, LC3A, and Ki-67 in gallbladder epithelium were studied using immunohistochemistry techniques. Beclin-1 expression was correlated with LC3A expression in group A with increased Beclin-1 expression promoting LC3A expression (p =0.0001). In group B, the LC3A expression did not follow Beclin-1 expression (p =0.09). The mean percentage of Beclin-1 expression in group A patients was 23.8 % compared to group B patients, where the corresponding percentage was only 17.3 %. Corresponding mean percent expressions of LC3A in groups A and B were 38.9 % and 50.7 %, respectively. The expression of Ki-67 was higher in group A patients compared to group B patients. The mean percentage of Ki-67 expression in group A patients was 3.75 %, whereas, in group B patients, it was only 0.5 % (statistically significantly different; p =0.0003). In the epithelium of calculous cholecystitis, overexpression of LC3A is related to Beclin-1 overexpression, which reinforces the view that Beclin-1 promotes autophagy in stone cholecystitis. HIPPOKRATIA 2019, 23(2): 64-69.
Sections du résumé
BACKGROUND
BACKGROUND
Autophagy is an inducible intracellular process that has been studied mostly in cancer and less in inflammatory diseases. To establish the relation between cholecystitis (calculous and acalculous) and autophagy, we studied the expressions of immunohistochemical markers Beclin-1, LC3A, and Ki-67 in gallbladder epithelium and their significance in the induction of autophagy.
METHODS
METHODS
Adult human gallbladder tissues were obtained from 100 patients (45 male, 55 female) who underwent cholecystectomy. According to the findings, the patients were divided into two groups: group A (calculous gallbladder: 24 male, 46 female; mean age 52.6 ± 16.0 years) and group B (acalculous gallbladder: 21 male, nine female; mean age 65.3 ± 12.4 years). The expressions of immunohistochemical markers Beclin-1, LC3A, and Ki-67 in gallbladder epithelium were studied using immunohistochemistry techniques.
RESULTS
RESULTS
Beclin-1 expression was correlated with LC3A expression in group A with increased Beclin-1 expression promoting LC3A expression (p =0.0001). In group B, the LC3A expression did not follow Beclin-1 expression (p =0.09). The mean percentage of Beclin-1 expression in group A patients was 23.8 % compared to group B patients, where the corresponding percentage was only 17.3 %. Corresponding mean percent expressions of LC3A in groups A and B were 38.9 % and 50.7 %, respectively. The expression of Ki-67 was higher in group A patients compared to group B patients. The mean percentage of Ki-67 expression in group A patients was 3.75 %, whereas, in group B patients, it was only 0.5 % (statistically significantly different; p =0.0003).
CONCLUSION
CONCLUSIONS
In the epithelium of calculous cholecystitis, overexpression of LC3A is related to Beclin-1 overexpression, which reinforces the view that Beclin-1 promotes autophagy in stone cholecystitis. HIPPOKRATIA 2019, 23(2): 64-69.
Types de publication
Journal Article
Langues
eng
Pagination
64-69Informations de copyright
Copyright 2019, Hippokratio General Hospital of Thessaloniki.
Déclaration de conflit d'intérêts
The authors declare no financial interests and conflicts of interest regarding any of the products or methods used in this study. This research did not receive any specific grant or funding from agencies in the public, commercial, or not-for-profit sectors.
Références
Lab Invest. 2010 Jun;90(6):835-43
pubmed: 20212459
Anticancer Res. 2018 Dec;38(12):6827-6833
pubmed: 30504397
Am J Pathol. 2010 May;176(5):2477-89
pubmed: 20382705
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Br J Cancer. 2013 Feb 5;108(2):271-7
pubmed: 23329234
J Biomed Sci. 2019 Feb 14;26(1):19
pubmed: 30764829
Hepatogastroenterology. 2014 Sep;61(134):1494-500
pubmed: 25436332
Genes Dev. 2009 Apr 1;23(7):784-7
pubmed: 19339684
Oncotarget. 2017 Oct 13;8(59):100614-100630
pubmed: 29246006
Cell Res. 2014 Jan;24(1):9-23
pubmed: 24366340
Semin Cell Dev Biol. 2015 Mar;39:43-55
pubmed: 25724561
Clin Exp Med. 2008 Sep;8(3):165-70
pubmed: 18791690
J Virol. 1998 Nov;72(11):8586-96
pubmed: 9765397
Cell. 2008 Jan 11;132(1):27-42
pubmed: 18191218
Head Neck Pathol. 2020 Mar;14(1):150-155
pubmed: 30977096
J Clin Invest. 1968 May;47(5):1043-52
pubmed: 5645851
Mod Pathol. 2001 Mar;14(3):185-90
pubmed: 11266524
Environ Health Prev Med. 2018 Oct 20;23(1):50
pubmed: 30340457
Cancer Biol Med. 2018 Aug;15(3):260-274
pubmed: 30197793
Autophagy. 2011 Nov;7(11):1371-8
pubmed: 21997374
Hematol Oncol Stem Cell Ther. 2013 Mar;6(1):20-5
pubmed: 23664601
J Oncol. 2019 Apr 1;2019:2343876
pubmed: 31057611
Hum Pathol. 2012 Apr;43(4):489-95
pubmed: 21937080
Zhonghua Jie He He Hu Xi Za Zhi. 2019 Mar 12;42(3):185-192
pubmed: 30845395
Eur Spine J. 2016 Dec;25(12):4016-4024
pubmed: 26399506
Rev Col Bras Cir. 2012 Sep-Oct;39(5):394-400
pubmed: 23174791
Nature. 1999 Dec 9;402(6762):672-6
pubmed: 10604474